PRFX PainReform Accounting Capitalization

Public company logo of PainReform (PRFX)

PainReform Ltd. (PRFX) specializes in developing innovative solutions for long-term postoperative pain management, utilizing technology that optimizes clinic service costs by accelerating patient recovery. Business growth is driven by the completion of final PRF-110 trials and pending FDA approval. The current metric stands at 0.00. The quotes provided below on GURU.Markets complement data regarding a stable expert staff and low employee turnover.

PRFX PainReform Corp Book Capitalization (07/04/2022 - 10/27/2026)

Metric breakdowns and analytics for PainReform (PRFX)

- price and consensus price forecast:
Quote Chart PainReform Corp|PRFX - Consensus Target
- market capitalization data:
Market Capitalization PainReform Ltd|PRFX - Total Company Value
- book capitalization data:
Share Book Value PainReform|PRFX - Book Capitalization|Market Value to Book Value painreform.com|PRFX - Company Total Assets
- debt and liquidity data:
Total Debt to Capital PainReform Ltd.|PRFX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital PainReform Ltd|PRFX - Company Debts|Debt to Book Value PainReform Ltd
Fundamental valuation:PRFX - PainReform Corp
Flagship merchandise of PainReform Ltd

Book value, represented by the current carrying amount of equity, measures the residual value of net assets after all liabilities are settled, establishing the fundamental safety threshold for investments. For PainReform Ltd. (PRFX), this indicator serves as a defensive buffer during the completion of PRF-110 clinical trials, allowing for an assessment of the business's actual material stability prior to receiving regulatory approvals and a potential revision of market value.

Competitor analysis for PainReform Ltd.

Haleon Corp (HLN) - Net Asset Value|Company Net Assets Kenvue Inc.|VRNA (veronapharma.com) - Accounting Capitalization|Company Book Value Jyong Biotech MENS|Net Asset Value Ligand Pharmaceuticals Incorporated|Amneal Pharmaceuticals Inc (AMRX) - Book Capitalization|Accounting Value of Company Perrigo Corp (PRGO)|Book Capitalization ALVO (Alvotech)|liquidia.com - Book Capitalization|Company Book Value Galapagos (GLPG)|ANIP: Accounting Value of Company|MNKD (MannKind Corp.) - Company Book Value|Amphastar Corp (AMPH) - Company Net Assets|PCRX (Pacira BioSciences) - Book Capitalization|Book Capitalization ars-pharma.com (SPRY)|Theravance Biopharma, Inc. (TBPH) - Company Net Assets|Accounting Value of Company AQST (Aquestive Therapeutics Inc)|SCPH: Company Book Value|TECX - Total Stockholders' Equity|Company Net Assets Tonix Pharmaceuticals TNXP|SXTC - Total Net Assets|Book Capitalization eupraxiapharma.com EPRX|BioHarvest Sciences, Inc. (BHST) - Accounting Value of Company|Book Capitalization EXOZ (Invizyne Technologies, Inc.)|Total Stockholders' Equity ORMP|Entera Bio Ltd. (ENTX) - Company Book Value|Accounting Value of Company HYFT (ipatherapeutics.com)|ABVC BioPharma, Inc. (ABVC) - Company Book Value|Net Asset Value Cumberland Pharmaceuticals Inc CPIX|Quantum BioPharma Limited - Book Capitalization|FGEN - Book Capitalization|Telomir Pharmaceuticals - Book Capitalization|RANI (Rani Therapeutics Holdings, Inc.) - Book Valuation of Business|Company Book Value Synergy CHC Corp. (SNYR)|Accounting Capitalization RLYB|Lexaria Bioscience (LEXX) - Company Book Value|Accounting Value of Company Pulmatrix Corporation (PULM)|PTHL: Book Capitalization|Total Stockholders' Equity Aptorum Group Ltd APM|Book Capitalization Lyra Therapeutics|IBO: Net Asset Value|Company Book Value TNFA|YCBD (cbdMD) - Total Stockholders' Equity|CYTO - Company Book Value|Accounting Value of Company LIPO|Company Book Value OPTN (OptiNose)|Company Net Assets Pieris Pharmaceuticals Inc PIRS|Company Net Assets Procaps Group SA|Petros Pharma - Accounting Value of Company|QLI - Company Book Value|acelyrin.com (SLRN) - Company Book Value|TFFP - Company Net Assets